Musculoskeletal Pain Market Poised for Transformation During the Forecast Period (2026-2036) as Novel Therapies and Non-Opioid Approaches Reshape Treatment | DelveInsight

This is more of a TAM-validation signal than a near-term revenue event. The investable angle is that if one regenerative/disease-modifying therapy gets credible clinical and regulatory traction, the market stops pricing the space as a commoditized injection business and starts assigning option value to procedure replacement, which is where the multiple expansion lives.

MESO is the clearest asymmetrical beneficiary because durable functional benefit would move it from a niche pain asset to a potential pathway to deferral of repeat steroid/viscosupplement use and, in a subset, surgery. The flip side is that payers will not pay for narrative; they will pay for fewer procedures, better function, and lower downstream utilization, so any benefit that does not translate into hard economics will cap adoption quickly. PCRX is the main incumbent exposed to that shift, but only if investors begin to believe the new category is real rather than promotional.

The contrarian view is that the market is likely overestimating how fast specialist pain workflows change. Even with positive data, uptake is usually gated by coding, prior auth, and physician habit, so the first 1-3 months after catalysts can be driven by sentiment while 6-18 months determine whether this is a durable category or another small-commercialization disappointment. Falsifiers for the bullish MESO read are weak durability, ambiguous functional endpoints, FDA friction, or pricing that lands below the economics of repeat injections.